Accessibility Menu
Cardiol Therapeutics logo

Cardiol Therapeutics(TSX) CRDL

Market CapCA$315.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-35%
5 Year-40%
1 Year+85%
1 Month+56%
CA$2.75
+1.85%
+0.05Today
Cardiol Therapeutics last closing stock price
MetricPriceDate
Last closeCAD 2.752026-08-31
Cardiol Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+6.59%CAD 2.582026-08-24
1 month+56.25%CAD 1.762026-07-31
3 month+68.71%CAD 1.632026-06-02
Year to date+109.92%CAD 1.312025-12-31
1 year+84.56%CAD 1.492025-08-29
3 year+103.7%CAD 1.352023-09-01
5 year-39.69%CAD 4.562021-09-01
Since inception-34.94%CAD 4.152018-12-20

Cardiol Therapeutics Financials at a Glance

Market Cap

CA$315.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CA$0.00

Net Income (TTM)

-CA$34.08M

EPS (TTM)

-CA$0.34

P/E Ratio

-7.90

Dividend

CA$0.00

Beta (Volatility)

1.69 (High)

Price

CA$2.75

Volume

186,407

Open

CA$2.70

Previous Close

CA$2.75

Daily Range

CA$2.62 - CA$2.75

52-Week Range

CA$1.23 - CA$3.15

Estimated Earnings Date

Nov 12, 2026

CRDL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cardiol Therapeutics

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on developing innovative treatments for cardiovascular diseases, particularly targeting fibrosis and inflammation. The company's flagship product, CardiolRx, is currently in a Phase II/III international clinical trial aimed at evaluating its efficacy and safety in patients hospitalized with COVID-19 and addressing acute myocarditis.

Products and Services
  • CardiolRx: A heart-protective therapy in clinical trials
  • Injectable formulation targeting cardiac scarring and inflammation
  • Research and development in cardiovascular disease treatments
Growth Outlook
  • Ongoing Phase II/III trial could lead to significant market opportunities
  • Strong focus on addressing unmet needs in cardiovascular health
  • Potential expansion into new therapeutic areas beyond current focus
Financial Highlights
  • Cash and cash equivalents of CAD 27.67 million as of March 31, 2026
  • Operating expenses of CAD 9.68 million in Q1 2026
  • Net income of CAD -10.82 million for Q1 2026, reflecting ongoing investment in R&D
Cardiol Therapeutics Inc. is positioned in a critical sector of healthcare, focusing on cardiovascular diseases, which remain a leading cause of morbidity and mortality worldwide. The ongoing clinical trials for CardiolRx represent a significant step towards addressing urgent health challenges, particularly in the context of COVID-19. With a robust cash position, the company is well-equipped to continue its research and development efforts, potentially leading to groundbreaking therapies in the cardiovascular space. The financial data indicates a commitment to innovation, with substantial investments in research and development, which may yield long-term benefits as the company progresses through its clinical trials.
AI Generated • Aug 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

23

CEO

David G. Elsley, MBA

Website

www.cardiolrx.com

Headquarters

Oakville, ON L6H 0G5, CA

CRDL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-180.13%

Return on Capital

-190.61%

Return on Assets

-116.08%

Earnings Yield

-12.66%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

CA$315.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

116.82M

Volume

186.41K

Avg. Volume

129.54K

Financials (TTM)

Gross Profit

-CA$89.78K

Operating Income

-CA$35.86M

EBITDA

-CA$35.55M

Operating Cash Flow

-CA$24.05M

Capital Expenditure

-CA$56.73K

Free Cash Flow

-CA$24.10M

Cash & ST Invst.

CA$26.08M

Total Debt

CA$107.00K

Cardiol Therapeutics Performance Analysis

Cardiol Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CAD 0N/A
20232023-12-31CAD 0N/A
20242024-12-31CAD 0N/A
20252025-12-31CAD 0N/A
Cardiol Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
Cardiol Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CAD -0.49-32.4%
20232023-12-31CAD -0.44-11.8%
20242024-12-31CAD -0.5117.4%
20252025-12-31CAD -0.39-24.1%
Cardiol Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-20.0%
Q42025-12-3140.1%
Q12026-03-31-38.1%
Q22026-06-3046.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CA$0.00

N/A

Gross Profit

-CA$11.55K

+54.7%

Gross Margin

0.00%

N/A

Market Cap

CA$315.42MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

CA$17.52M

N/A

Employees

18

N/A

Net Income

-CA$6.08M

+27.2%

EBITDA

-CA$7.93M

-3.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CA$26.08M

+43.3%

Total Debt

CA$107.00K

-24.9%

Accounts Receivable

CA$312.61K

+11.7%

Inventory

CA$0.00

N/A

Long Term Debt

CA$65.69K

-38.6%

Short Term Debt

CA$41.31K

+16.2%

Return on Assets

-1.16%

N/A

Return on Invested Capital

-1.49%

N/A

Free Cash Flow

-CA$4.38M

+3.8%

Operating Cash Flow

-CA$4.38M

+3.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RX.VBioSyent Inc.
CA$15.99+1.52%
LOVE.VCannara Biotech Inc.
CA$1.89+6.18%
HLS.TOHLS Therapeutics Inc.
CA$3.75-1.06%
ZEN.VZentek Ltd.
CA$0.70-9.09%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About CRDL

What is the current price of Cardiol Therapeutics?

Cardiol Therapeutics is trading at CA$2.75 per share.

What is the 52-week range for Cardiol Therapeutics?

Over the past 52 weeks, Cardiol Therapeutics has traded between CA$1.23 and CA$3.15.

How much debt does Cardiol Therapeutics have?

As of the most recent reporting period, Cardiol Therapeutics reported total debt of CA$107.00K.

How much cash does Cardiol Therapeutics have on hand?

Cardiol Therapeutics reported CA$26.08M in cash and cash equivalents in its most recent financial results.

What is Cardiol Therapeutics’s dividend yield?

Cardiol Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services